P2-281: Retrospective study on patients diagnosed with advanced Non-Small Cell Lung Cancer treated with the combination of gemcitabine and vinorelbine: assessment of therapeutic efficacy and prognosis factors

María Luque, Emilio Esteban, Norberto Corral, Noemi Villanueva, Paula Jimenez, Beatriz Llorente, Marta Capelan, José Pablo Berros, Guillermo Crespo, Angel J Lacave
2007 Journal of Thoracic Oncology  
Gemcitabine (G), vinorelbine (V) and their combination (GV) have shown to be useful in patients with Non-Small Cell Lung Cancer (NSCLC). The purpose of this study has been to confirm the effectiveness (activity) of GV and to identify prognostic factors related with clinical outcomes. Methods: A retrospective analysis was carried out relating to 144 patients with NSCLC treated between October 1996 and April 2005 with G (1000-1250 mg/m 2 ) +V (25-30 mg/m 2 ) both administered on days 1 and 8
more » ... three weeks. Results: Treatment was well tolerated neutropenia grade 3-4 being registered as the worse toxicity in 18% of cases, including 7% of neutropenic fever. The objective response rate was 36.8% (95% CI: 28.9-44.7) and the median progression free survival and overall survival rates were 21 (18-25) and 33 (26-40) weeks respectively. In multivariate analysis only the histology of adenocarcinoma (HR 3; p<.0001), less than two metastatic sites (HR 1.7; p =.02)and Karnofsky index (KI) above 70 % (HR 1.5; p=.02) showed a significant association with longer survival. Conclusion: The combination of GV is well tolerated and active in patients with advanced NSCLC. The histology of adenocarcinoma, less than two metastatic sites and KI above 70 % have been identified as independent variables related with longer survival.
doi:10.1097/01.jto.0000283989.37954.ad fatcat:5lijcbkqinb6xowmnrujqgxx24